Advent Venture Partners, the UK-based venture capital firm, has made two deals in two days, leading the $70m (€72m) financing round for Infinity Pharmaceuticals, the US drug discovery company, and the €5m investment in Pertinence, a French software firm.

Other investors in Infinity included two existing venture capital investors and seven new lifesciences investors, including HBM Bioventure, Novartis Bioventure Fund, and the Wellcome Trust. Private investors also participated in the funding round.